Tislelizumab Plus Lenvatinib in Stage III-IV RCC

Clinical trial NCT05485883 · UNKNOWN

Trial details

NCT number: NCT05485883
Sponsor: Tianjin Medical University Second Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Kidney Cancer

Start date: 2022-07-01
Primary completion: 2023-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.